Nordea Investment Management AB Has $1.63 Million Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Nordea Investment Management AB raised its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 7.3% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 17,839 shares of the medical equipment provider’s stock after buying an additional 1,210 shares during the quarter. Nordea Investment Management AB’s holdings in Zimmer Biomet were worth $1,628,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Brighton Jones LLC bought a new position in Zimmer Biomet during the fourth quarter worth $204,000. GAMMA Investing LLC grew its position in Zimmer Biomet by 52.4% in the 1st quarter. GAMMA Investing LLC now owns 3,502 shares of the medical equipment provider’s stock worth $396,000 after purchasing an additional 1,204 shares during the last quarter. Janney Montgomery Scott LLC increased its holdings in shares of Zimmer Biomet by 0.5% during the 1st quarter. Janney Montgomery Scott LLC now owns 25,647 shares of the medical equipment provider’s stock worth $2,903,000 after purchasing an additional 118 shares during the period. Oppenheimer Asset Management Inc. raised its position in shares of Zimmer Biomet by 6.6% during the first quarter. Oppenheimer Asset Management Inc. now owns 10,923 shares of the medical equipment provider’s stock valued at $1,236,000 after buying an additional 672 shares during the last quarter. Finally, Asset Management One Co. Ltd. lifted its stake in shares of Zimmer Biomet by 2.0% in the first quarter. Asset Management One Co. Ltd. now owns 83,548 shares of the medical equipment provider’s stock valued at $9,456,000 after buying an additional 1,635 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Price Performance

Shares of ZBH stock opened at $103.87 on Thursday. The stock’s fifty day simple moving average is $101.83 and its 200 day simple moving average is $97.72. Zimmer Biomet Holdings, Inc. has a one year low of $89.22 and a one year high of $114.72. The firm has a market cap of $20.58 billion, a price-to-earnings ratio of 25.27, a P/E/G ratio of 2.36 and a beta of 0.67. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company had revenue of $2.08 billion during the quarter, compared to analysts’ expectations of $2.06 billion. During the same period last year, the business earned $2.01 earnings per share. The business’s revenue was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.36%.

Insider Activity

In other news, SVP Lori Winkler sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the transaction, the senior vice president directly owned 6,833 shares of the company’s stock, valued at $711,656.95. The trade was a 18.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.39% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on ZBH. Canaccord Genuity Group restated a “hold” rating and set a $101.00 price target on shares of Zimmer Biomet in a research note on Wednesday. Royal Bank Of Canada set a $111.00 price objective on Zimmer Biomet in a report on Friday, October 10th. Redburn Partners set a $130.00 target price on Zimmer Biomet in a research note on Thursday, September 18th. Rothschild Redb raised Zimmer Biomet to a “strong-buy” rating in a research report on Thursday, September 18th. Finally, UBS Group boosted their price target on shares of Zimmer Biomet from $91.00 to $96.00 and gave the company a “sell” rating in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $111.94.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.